Anatomy and pathology of HIV-1 peptidase

Essays in Biochemistry

Volumn 38, Issue , 2002, Pages 113-127

  Dunn, Ben M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PEPTIDASE; LIGAND; PEPTIDASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANATOMY; FELINE IMMUNODEFICIENCY VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATHOLOGY; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTION; VIRUS REPLICATION; VIRUS RESISTANCE;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0038732585     PISSN: 00711365     EISSN: None     Source Type: Journal    
DOI: 10.1042/bse0380113     Document Type: Review

References (22)

1. Tomasselli, A.G. & Heinrikson, R.L. (2000) Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim. Biophys. Acta 1477, 189-214
2. Swanstrom, R. & Erona, J. (2000) Human immunodeficiency virus type-I protease inhibitors: therapeutic successes and failures, suppression and resistance. Pharmacol. Ther. 86, 145-170
3. Wlodawer, A. & Gustchina, A. (2000) Structural and biochemical studies of retroviral proteases. Biochim. Biophys. Acta 1477, 16-34
4. Vondrasek, J. van Buskirk, C.P. & Wlodawer, A. (1997) Database of three-dimensional structures of HIV proteinases. Nat. Struct. Biol. 4, 8
5. Shao, W., Everitt, L., Manchester, M., Loeb, D.D., Hutchison, III, C.A. & Swanstrom, R. (1997) Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. Proc. Natl. Acad. Sci. U.S.A. 94, 2243-2248
6. Sardana, V.V., Schlabach, A.J., Graham, P., Bush, B.L., Condra, J.H., Culbertson, J.C., Gotlib, L., Graham, D.J., Kohl, N.E., LaFemina, R.L. et al. (1994) Human immundeficiency virus type I protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. Biochemistry 33, 2004-2010
7. Ridky, T.W., Kikonyoho, A., Leis, J., Gulnik, S., Copeland, T., Erickson, J., Wlodawer, A. Kurinov, I., Harrison, R.W. & Weber, I. (1998) Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. Biochemistry 37, 13835-13845
8. Mahalingam, B. Louis, J.M., Reed, C.C., Adomat, J.M. Krouse, J., Wang, Y.-F., Harrison, R.W. & Weber, I.T. (1999) Structure and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur. J. Biochem. 263, 238-245
9. Todd, M.J., Luque, I., Valazquez-Campoy, A. & Freire, E. (2000) Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/184V active site resistant mutant. Biochemistry 39, 11876-11883
10. Prabu-Jeyabalan, M. Nalivaika, E. & Schiffer, C.A. (2000) How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J. Mol. Biol. 301, 1207-1220
11. Laco, G.S., Schalk-Hihi, C., Lubkowski, J., Morris, G., Zdanov, A., Olson, A., Elder, J.H., Wlodawer, A. & Gustchina, A. (1997) Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor. Biochemistry 36, 10696-10708
12. Prabu-Jeyabalan, M., Nalivaika, E. & Schiffer, C.A. (2002) Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10, 369-381
13. Mahalingam, B., Louis, J.M., Hung, J., Harrison, R.W. & Weber, I.T. (2001) Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins: Struct. Funct. Genet. 43, 455-464
14. Wlodawer, A., Gustchina, A., Reshetnikova, L., Lubkowski, J., Zdanov, A., Hui, K.Y., Angleton, E.L., Farmerie, W.G., Goodenow, M.M., Bhatt, D. et al. (1995) Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat. Struct. Biol. 2, 480-488
15. Lin, Y.-C., Beck, Z., Lee, T., Le, V.-D., Morris, G.M., Olson, A.J., Wong, C.-H. & Elder, J.H. (2000) Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease. J. Virol. 74, 4710-4720
16. Li, M., Morris, G.M., Lee, T., Laco, G.S., Wong, C.-H., Olson, A.J., Elder, J.H., Wlodawer, A. & Gustchina, A. (2000) Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease. Proteins: Struct. Funct. Genet. 38, 29-40
17. Dunn, B.M., Pennington, M.W., Frase, D.C. & Nash, K. (1999) Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem. Biopolymers (Peptide Sci.) 51, 69-77
18. Kervinen, J., Lubkowski, J. Zdanov. A., Bhatt, D., Dunn, B.M., Hui, K.Y., Powell, D.J., Kay, J., Wlodawer, A. & Gustchina, A. (1998) Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV. Protein Sci. 7, 2314-2323
19. Hoog, S.S., Towler, E.M., Zhao, B., Doyle, M.L., Debouck, C. & Abdel-Meguid, S.S. (1996) Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity. Biochemistry 35, 10279-10286
20. Towler, E.M., Thompson, S.K., Tomaszek, T. & Debouck, C. (1997) Identification of a loop outside the active site cavity of the human immunodeficiency virus proteases which confers inhibitor specificity. Biochemistry 36, 5128-5133
21. Swairjo, M.A., Towler, E.M., Debouch, C. & Abdel-Meguid, S.S. (1988) Structural role of the 30's loop in determining the ligand specificity of human immunodeficiency virus protease. Biochemistry 37, 10928-10936
22. Rose, R.B., Craik, C.S. & Stroud, R.M. (1998) Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 37, 2607-2621